VedaBio Shows CRISPR Test Answers in Under 10 Minutes

A molecular result in under 10 minutes, with no amplification step, is the claim VedaBio carried to Seattle. The San Diego company presented proof-of-concept data at the Association for Molecular Pathology (AMP) 2026 Annual Meeting & Expo showing sample-to-answer times under 10 minutes from its integrated, target amplification-free CRISPR-based diagnostics technology.

The demonstration had a concrete shape. In the proof-of-concept study, VedaBio's integrated prototype ran a five-result respiratory panel, a multiplex test that looks for several targets in one run, and the workflow included automated nucleic acid extraction. Extraction is the unglamorous step that usually eats the clock before detection even starts, so folding it into the same under-10-minute window is the detail that matters.

Conventional molecular testing gets its sensitivity from amplification, copying a target's genetic material until there's enough of it to detect. That step costs time, equipment and complexity, and it's a large part of why molecular tests have stayed inside centralized laboratories. VedaBio's platform is built to detect targets without it, using CRISPR, and the company says the point is to carry molecular testing closer to patients, into urgent care and other decentralized settings.

Brett Robb, the company's chief scientific officer, presented the work as poster TT061, titled “Target-Amplification-Free CRISPR-Cas Nucleic Acid Detection with OR-Logic Multiplexing Enables Clinically Relevant, Rapid Point-of-Care Testing,” abstract number 2467268, in the Technical Topics session on Saturday, November 14, 2026, from 9:15 to 10:15 a.m. Pacific Time.

“Molecular diagnostics should not have to come with trade-offs between speed, complexity and performance,” Robb said. “Our goal is to challenge those limitations and bring the benefits of molecular testing closer to patients.” The company frames its platform around five pillars, speed, simplicity, breadth, accuracy and economics, which is a list of exactly the properties a point-of-care test has to hold at once to displace a lab.

The honest label on all of this is proof of concept. VedaBio's own announcement calls the data preliminary progress toward a platform, not a cleared product a clinic can order, and it doesn't publish sensitivity or specificity figures for the panel in the release. A fast answer that isn't an accurate one helps nobody, and the numbers that would settle that question aren't in this announcement.

What the Seattle poster establishes is narrower and still useful: an integrated prototype, an automated extraction step, five respiratory results, and a clock that stopped under 10 minutes. The next evidence that counts is comparative accuracy data, and VedaBio hasn't put it on the table yet.